Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...